Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California.

Founded in September 2016 by Charlene Liao, the company focuses on developing innovative biotherapeutics that target myeloid cell inhibitory receptors. Their mission is to enhance the lives of patients with challenging cancers and autoimmune diseases through the creation of novel myeloid checkpoint inhibitors. The company has a dedicated team of 18 to 24 employees and has successfully raised $138 million in funding, including a significant $73 million in Series B1 and B2 financing in March 2021. Immune-Onc is advancing a pipeline of drug candidates, including IO-202 for acute myeloid leukemia and IO-108 for solid tumors and hematologic malignancies. Their approach aims to disarm immune suppression in the tumor microenvironment, allowing the immune system to effectively target cancer cells. Immune-Onc collaborates with scientists, academic institutions, and non-profit organizations to further their research and development efforts.